iTeos Therapeutics (NASDAQ:ITOS) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research report sent to investors on Friday morning,Benzinga reports. They currently have a $46.00 target price on the stock.

A number of other equities research analysts have also commented on the stock. JPMorgan Chase & Co. reduced their price objective on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Tuesday. Finally, Wells Fargo & Company initiated coverage on shares of iTeos Therapeutics in a research note on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 price objective on the stock.

iTeos Therapeutics Stock Performance

Shares of NASDAQ:ITOS traded down $0.23 during trading on Friday, reaching $8.23. The stock had a trading volume of 1,052,727 shares, compared to its average volume of 442,983. The firm’s fifty day moving average is $10.27 and its 200 day moving average is $13.97. iTeos Therapeutics has a 52 week low of $7.99 and a 52 week high of $18.75. The stock has a market cap of $300.64 million, a price-to-earnings ratio of -2.61 and a beta of 1.39.

Hedge Funds Weigh In On iTeos Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ITOS. nVerses Capital LLC boosted its position in shares of iTeos Therapeutics by 212.5% in the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after acquiring an additional 1,700 shares during the period. Point72 DIFC Ltd bought a new stake in shares of iTeos Therapeutics during the 3rd quarter worth $31,000. China Universal Asset Management Co. Ltd. increased its stake in iTeos Therapeutics by 60.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after acquiring an additional 2,646 shares during the last quarter. Quest Partners LLC increased its stake in iTeos Therapeutics by 914.7% in the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock valued at $113,000 after acquiring an additional 9,934 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in iTeos Therapeutics by 6.6% in the second quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock valued at $164,000 after acquiring an additional 690 shares during the last quarter. Institutional investors own 97.16% of the company’s stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.